Interesting, page-4827

Rusty, I suspect the new and larger premises was part of their long term strategy that's now come to fruition.
The inference I can take from that move is that the Co can see growth in both business expansion opportunities
and ramped-up manufacturing ambitions. We're just seeing the microcosm of our market potential.

If we can (1) increase our patient enrolments as canvased many times (multiple sites will now help enormously)
and (2)keeping shareholders updated, both these aspects of the business are vital to propping up investor
sentiment.

Hopefully, the inordinate amount of time taken so far to enrol patients changes and we can then begin to see a
more compelling strategy play out both from an SP perspective and a technology perspective, because proving
those bio-safe nanoparticles that are cancer-specific and can attach to tumour cells and work as an imaging
agent safely is what will ultimately ignite the big rocket.